Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Zannikos

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Clinical Pharmacokinetics|August 5, 2023
Correction to: Pharmacokinetics of Nasal Esketamine in Patients with Allergic Rhinitis with and Without Nasal Decongestant Pretreatment and in Healthy Subjects with and Without Nasal Corticosteroid PretreatmentPeter Zannikos, Bhavna Solanki, Marc De Meulder, et al.
British Journal of Clinical Pharmacology|July 18, 2006
Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patientsJuan Jose Perez-Ruixo, Vladimir Piotrovskij, Steven Zhang, et al.
Epilepsia|May 21, 2009
Pharmacokinetics of carisbamate (RWJ-333369) in healthy Japanese and Western subjectsPeter Zannikos, Gerald Novak, Caiping Yao, et al.
British Journal of Clinical Pharmacology|May 8, 2002
The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramineSally Usdin Yasuda, Peter Zannikos, Andrea E Young, et al.
Clinical Pharmacokinetics|October 31, 2020
Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant DepressionCarlos Perez-Ruixo, Stefaan Rossenu, Peter Zannikos, et al.
Pediatric Blood & Cancer|August 1, 2012
A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumorsMeredith K Chuk, Alberta Aikin, Trish Whitcomb, et al.
Journal of Pain Research|July 16, 2019
First evaluation of tapentadol oral solution for the treatment of moderate to severe acute pain in children aged 6 to <18Julia C Finkel, Jutta Goldberg, Ronald Rosenburg, et al.
Drug Design, Development and Therapy|March 6, 2025
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Milvexian in Healthy Chinese AdultsZhu Luo, Jie Wang, Zhuolu Niu, et al.
Clinical Pharmacokinetics|September 15, 2007
Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patientsJuan Jose Perez-Ruixo, Peter Zannikos, Sarapee Hirankarn, et al.
Journal of Clinical Pharmacology|September 22, 2006
Pharmacokinetics of tipifarnib after oral and intravenous administration in subjects with advanced cancerSteven Zhang, Peter Zannikos, Ahmad Awada, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Clinical Pharmacokinetics|August 5, 2023
Correction to: Pharmacokinetics of Nasal Esketamine in Patients with Allergic Rhinitis with and Without Nasal Decongestant Pretreatment and in Healthy Subjects with and Without Nasal Corticosteroid PretreatmentPeter Zannikos, Bhavna Solanki, Marc De Meulder, et al.
British Journal of Clinical Pharmacology|July 18, 2006
Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patientsJuan Jose Perez-Ruixo, Vladimir Piotrovskij, Steven Zhang, et al.
Epilepsia|May 21, 2009
Pharmacokinetics of carisbamate (RWJ-333369) in healthy Japanese and Western subjectsPeter Zannikos, Gerald Novak, Caiping Yao, et al.
British Journal of Clinical Pharmacology|May 8, 2002
The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramineSally Usdin Yasuda, Peter Zannikos, Andrea E Young, et al.
Clinical Pharmacokinetics|October 31, 2020
Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant DepressionCarlos Perez-Ruixo, Stefaan Rossenu, Peter Zannikos, et al.
Pediatric Blood & Cancer|August 1, 2012
A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumorsMeredith K Chuk, Alberta Aikin, Trish Whitcomb, et al.
Journal of Pain Research|July 16, 2019
First evaluation of tapentadol oral solution for the treatment of moderate to severe acute pain in children aged 6 to <18Julia C Finkel, Jutta Goldberg, Ronald Rosenburg, et al.
Drug Design, Development and Therapy|March 6, 2025
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Milvexian in Healthy Chinese AdultsZhu Luo, Jie Wang, Zhuolu Niu, et al.
Clinical Pharmacokinetics|September 15, 2007
Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patientsJuan Jose Perez-Ruixo, Peter Zannikos, Sarapee Hirankarn, et al.
Journal of Clinical Pharmacology|September 22, 2006
Pharmacokinetics of tipifarnib after oral and intravenous administration in subjects with advanced cancerSteven Zhang, Peter Zannikos, Ahmad Awada, et al.
Pageof 4